US-REGISTERED COMPANY
Skip to product information
Peptiva peptides
Research Compound Semaglutide
€68,00
Sale price
€68,00
Regular price
€80,00
FOR IN VITRO LABORATORY RESEARCH ONLY.
Not intended for personal, clinical, diagnostic or veterinary use, or for administration to humans or animals.
Laboratory dispenser format
This description applies to the dispenser-format variant, not the vial-format variant.
The dispenser is a laboratory packaging and material-dispensing format. Product identity, declared quantity and storage conditions are stated in the specification for the individual material.
Laboratory dispensing format. It is not an injection or medical device and is not intended for administration to humans or animals.
MAIN RESEARCH AREAS Research profile
Editorial map of the main themes found in the scientific literature. Bar length is not a statistical score, efficacy rating, or indication for human use.
Description and specifications
Research Compound Semaglutide is a laboratory material for analytical and in vitro work, available in 2 mg and 5 mg variants.
What is semaglutide?
Semaglutide is a 31-amino-acid analogue of the human hormone GLP-1 with a molecular weight of approximately 4.1 kDa. Compared with native GLP-1(7-37) it contains three key modifications: aminoisobutyric acid at position 8, arginine at position 34, and a C18 fatty diacid chain attached to lysine via a linker.
Research background
Semaglutide was developed by Novo Nordisk as a successor to earlier GLP-1 analogues. Regulated pharmaceutical preparations containing semaglutide are approved medicines with their own documentation, which does not apply to research materials.
Mechanism and scientific context
Native GLP-1 is degraded by the enzyme DPP-4 within minutes. Aminoisobutyric acid at position 8 protects the molecule from this enzyme, and the fatty chain enables albumin binding. Together these modifications extend the half-life from a few minutes to about one week — a textbook example of rational peptide design. Semaglutide is a selective GLP-1 receptor agonist.
Main research areas
- the GLP-1 receptor
- peptide resistance to DPP-4
- albumin binding and pharmacokinetics
- rational design of peptide analogues
Level of evidence
A high level of clinical evidence exists for approved pharmaceutical preparations. This does not confirm the identity, purity or bioequivalence of this research material.
Related
See also Tirzepatide and Retatrutide.
Research use only: for laboratory, analytical and in vitro research only; not for use in humans or animals. Not a medicine. Guidance on batch documentation is available in our COA guide.
PEPTIVA PRO E-BOOK · DIGITAL EDITION
Explore the scientific context in greater depth
The expanded guide covers more than 50 compounds, mechanisms of action, levels of evidence, limitations of the available data and research regimens reported in publicly available scientific literature.
- 50+ compounds covered in detail
- Preclinical and clinical data clearly distinguished
- Experimental approaches described in scientific literature
- COA, purity and documentation
Educational content is not medical advice, a recommendation for self-administration or instructions for using products sold in this store.
COA on request
To enquire about a certificate of analysis (COA), send the material name, requested variant and LOT / batch number if available. Documents are not published on this page.
Request a COA by emailThe button opens your email app with a prepared enquiry. You send the message yourself. peptivapeptides@protonmail.com
A COA applies to a specific batch and documents the analytical parameters tested for that batch. The product is intended strictly for laboratory, analytical and in vitro research.